Traders Flee Pharma Junk Bonds as Price Scandal Engulfs IndustryBy
Scrutiny spreads past $750-a-pill move by Shkreli's Turing
Lawmakers pump `fear into sector'; new deals await fate
Pharmaceutical companies are emerging as the latest pocket of sorrow in the beleaguered junk-bond market as a renewed public debate on drug-pricing tactics unnerves investors.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.